Harrow: Pay

Harrow paid its 5 named executives $37.9M in total in FY2025 (Dec). CEO Francis W. Mullery was paid $1.2M of that.

Pay$100 in the stock at the end of FY21 → $828
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Mark L. BaumChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Andrew R. BollPresident and Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Amir H. ShojaeiChief Scientific Officer
FY2025 (Dec)
1 year
Francis W. MulleryPresident and Chief Executive Officer, ImprimisRx Division
FY2025 (Dec)
1 year
John P. SaharekFormer President and Chief Executive Officer, ImprimisRx Division
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $7.7M. CEO pay of Harrow for that year is not on file.

  1. 1Ocular Therapeutix
  2. 2Mirum Pharmaceuticals
  3. 3Ardelyx
  4. 4Staar Surgical
  5. 5Tarsus Pharmaceuticals
  6. 6Agios Pharmaceuticals
  7. 7HarrowNot disclosed
  8. 8Ani PharmaceuticalsNot disclosed
  9. 9Arrowhead PharmaceuticalsNot disclosed
  10. 10Dynavax TechnologiesNot disclosed
  11. 11Eyepoint PharmaceuticalsNot disclosed
  12. 12Heron TherapeuticsNot disclosed
  13. 13Ironwood PharmaceuticalsNot disclosed
  14. 14Rigal PharmaceuticalsNot disclosed
  15. 15RxSightNot disclosed
  16. 16Theravance BiopharmaNot disclosed
  17. 17Xeris Biopharma HoldingsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.